Tesamorelin
Tesamorelin after discontinuation
Continued treatment sustained a visceral-fat reduction. Withdrawal brought reaccumulation. Both findings belong in an account of benefit.
The withdrawal finding
The 52-week tesamorelin program in adults with HIV and abdominal fat accumulation reported a sustained -18% visceral-fat change during continued treatment, relative to baseline. Visceral fat reaccumulated after discontinuation. That second observation explains why I started Freebase Peptides here.
It would be easy to treat reaccumulation as an embarrassing qualification to an otherwise good result. To me, that continuation increases the result’s usefulness. The treatment was changing an ongoing process, and the benefit depended on continued treatment. A person weighing that benefit needs the continuing obligation in the picture from the beginning.
The paper’s population matters just as much as its follow-up: adults with HIV-associated abdominal fat accumulation. The approved indication is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. General weight loss and anti-aging extend beyond that indication.
A hormone rhythm and its downstream effects
Tesamorelin is a synthetic 44-amino-acid analogue of growth hormone-releasing hormone, GHRH. Its N-terminal modification helps it resist enzymatic breakdown. It stimulates the pituitary to release endogenous growth hormone, which in turn stimulates production of IGF-1 in the liver. The healthy-men mechanistic study examined that pulsatile hormone response.
In 13 healthy men over 2 weeks, mean overnight GH rose by 0.5 µg/L and IGF-1 by 181 µg/L, while fasting glucose and insulin-stimulated glucose uptake were not significantly affected. Those men’s hormone responses make an interesting mechanistic window. Longer-term safety in people with different metabolic conditions requires its own evidence.
Stimulating a hormone rhythm helps explain why visceral-fat changes can depend on continued intervention. It supplies a plausible account of the withdrawal finding; the clinical evidence of reaccumulation still comes from following people after they stopped.
Imaging results
The 2014 randomized JAMA trial enrolled 50 antiretroviral-treated adults with HIV. Over 6 months, the treatment effect on visceral-fat area was -42 cm², and the net change in hepatic lipid-to-water percentage was -2.9%. The outcomes came from measurements of particular fat compartments. Reading them as a general change in body weight would alter the result.
A 2026 meta-analysis of five randomized trials in HIV-associated lipodystrophy reported mean visceral adipose tissue change of -27.71 cm², trunk fat change of -1.18 kg, hepatic fat fraction change of -4.28%, and lean body mass change of +1.42 kg. The pooled result strengthens the evidence for those outcomes in that population.
I pair the withdrawal observation with these reductions because a scan during treatment establishes only the on-treatment response. The later observation tells us about sustaining it.
Approval, IGF-1 and glucose
Tesamorelin received U.S. approval in 2010 for its specific HIV-associated lipodystrophy indication. The LiverTox monograph describes it as an unlikely cause of clinically apparent liver injury and reports no attributable cases. That is reassuring on the liver-injury question. It leaves the other safety questions to their respective evidence.
The source material flags elevated IGF-1, active malignancy as a labelled contraindication, possible glucose perturbations and limited long-term oncologic safety data. The 52-week report found no clinically significant glucose changes over that period. These observations can coexist with a need for individual clinical monitoring. Tesamorelin is also prohibited in sport under WADA’s S2 category in the status recorded here.
I’m satisfied that there is a real, population-specific benefit to discuss. The harder part of the discussion is its duration and burden: continued treatment, the monitoring it entails, and reaccumulation after withdrawal. The comparison with MOTS-c and retatrutide shows why those conclusions cannot simply travel between compounds.